NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers

• Status: Not yet recruiting
• Trial end date: 2024-01-01

Summary

This is a multi-centre, long term, double blind, clinical protocol for NanaBis™ as a monotherapy treatment in participants 18-70 years of age with cancer related pain.

• Phase: Phase 3

Details

• Lead Sponsor: Medlab Clinical
• Collaborators: George Clinical Pty Ltd; WriteSource Medical Pty Ltd
• Treatments: Oxycodone